Sign In
Buy LLY
$1,231.58
+45.87 (+3.87%)
At Close: Aug 10, 2026
Is Biotech Immunocore About To Make A 25% Price Move?
07:00am, Tuesday, 07'th Feb 2023
The industry is home to some large-cap heavyweights, including Amgen Inc. (NASDAQ: AMGN), Gilead Sciences Inc. (NASDAQ: GILD), Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), Vertex Pharmaceuticals Inc
5 Best and Worst Performing Mega-Cap Stocks in January 2023
10:53pm, Friday, 03'rd Feb 2023
The stock market finished January on a positive note. This is a good sign for investors, who incurred huge losses last year.
AbbVie Q4 Preview: What's in Store?
06:49pm, Friday, 03'rd Feb 2023
AbbVie has put in a mixed earnings performance, exceeding bottom line estimates in five consecutive quarters but falling short of sales expectations in each instance.
Lilly (LLY) Reports Q4 Earnings: What Key Metrics Have to Say
08:17am, Friday, 03'rd Feb 2023
While the top- and bottom-line numbers for Lilly (LLY) give a sense of how the business performed in the quarter ended December 2022, it could be worth looking at how some of its key metrics compare t
Lilly (LLY) Beats on Q4 Earnings, Lags on Sales, Raises '23 View
06:05pm, Thursday, 02'nd Feb 2023
Eli Lilly's (LLY) earnings surpass fourth-quarter estimates while sales slightly miss the mark. The company raises its EPS guidance for 2023.
Merck, Eli Lilly stocks fall over earnings, outlook concerns
03:30pm, Thursday, 02'nd Feb 2023
Senior reporter Anjalee Khemlani joins Yahoo Finance Live to discuss how pharma stocks are faring after reporting earnings.
Pharma earnings: COVID ‘is highly uncertain for this year,' analyst says
02:36pm, Thursday, 02'nd Feb 2023
Pharma Wells Fargo Managing Director Mohit Bansal joins Yahoo Finance Live anchors Rachelle Akuffo and Anjalee Khemlani to discuss pharmaceutical earnings amid COVID uncertainty, the impact of diabeti
Eli Lilly and Company (LLY) Q4 2022 Earnings Call Transcript
02:25pm, Thursday, 02'nd Feb 2023
Eli Lilly and Company (NYSE:LLY ) Q4 2022 Earnings Conference Call February 2, 2023 10:00 AM ET Company Participants Joe Fletcher - Senior Vice President of Investor Relations Dave Ricks - Chairman &
Lilly's ambitious diabetes drug Mounjaro fails to impress in the fourth quarter
01:49pm, Thursday, 02'nd Feb 2023
Eli Lilly's LLY, -5.65% new Type 2 diabetes treatment Mounjaro may be in high demand, but the drug had a wobbly fourth quarter, with sales coming in far below Wall Street's expectations.
Why Eli Lilly Stock Is Under Pressure Today
12:15pm, Thursday, 02'nd Feb 2023
The drugmaker's fourth-quarter earnings failed to impress investors.
Eli Lilly CEO weighs in on Q4 revenue miss
09:49am, Thursday, 02'nd Feb 2023
Eli Lilly CEO David Ricks joins 'Squawk Box' to discuss the company's change in guidance, the outlook for the company's Diabetes drug, and Eli Lilly's manufacturing capacity of the new drug, Mounjaro.
Eli Lilly (LLY) Q4 Earnings Surpass Estimates
09:47am, Thursday, 02'nd Feb 2023
Lilly (LLY) delivered earnings and revenue surprises of 14.21% and 0.28%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Eli Lilly's stock falls after Q4 revenue miss
07:18am, Thursday, 02'nd Feb 2023
Eli Lilly & Co.'s LLY, -0.46% stock fell 2.3% before market open Thursday after the biopharmaceutical giant's fourth-quarter revenue came in below analysts' expectations. The company reported net inco
Eli Lilly Stock Falls Even as Earnings Crush Estimates
07:03am, Thursday, 02'nd Feb 2023
The pharmaceutical group reports earnings of $2.09 a share in the fourth quarter on revenue of $7.3 billion.
